Freeze v/s air-dried alginate-pectin gel beads modified with sodium dodecyl sulphate for enhanced removal of copper ions.

This work presents a novel polymer-based adsorbent, Sodium Dodecyl Sulphate modified alginate-pectin gel beads (APS221) prepared via controlled freeze drying & air drying, for the removal of copper ions from the aqueous solution. This work also critically discusses the role played by various components and their concentrations in the success of APS221. Addition of pectin to alginate resulted into approximately 150 % increase in the metal removal performance of the adsorbent while addition of SDS into alginate-pectin complex enhanced the performance by 14 % approximately, taking the maximum adsorption capacity of final complex APS221 to 111.11 mg/g. Our characterization studies revealed that the adsorption happened predominantly by complexation and ion-exchange mechanisms, and hence despite having a higher surface area, freeze-dried variant showed lesser adsorption capacity than air-dried variant as there was a loss of ion-exchange sites resulting from breakage of crosslinking bonds due to chain elongation. The adsorption process was found to follow Langmuir isotherm and pseudo-second order kinetics with a good fit of experimental data. Further, operating parameters have been optimized via RSM to, simultaneously, maximize the utilization of the adsorbent and minimize the cost of the process. Stability studies showed that APS221 beads could be used up to eight cycles.

Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature.

Reversible cerebral vasoconstriction syndrome (RCVS) is Raynaud's phenomenon of the brain. Changes in neurological function are dependent upon which areas of the brain are deprived of normal blood flow. Antiphospholipid antibody syndrome (APLA) is a common cause of Raynaud's phenomenon that can occur anywhere in the body, including the brain. Management of CNS vasospasm generally involves the use of centrally acting calcium channel blockers, which have been shown to relieve the associated headaches and transient neurological symptoms associated with it. Three patients with APLA and RCVS from our clinics are illustrated. It is demonstrated that the use of centrally acting calcium channel-blocking drugs, such as nimodipine, which prevent and reverse CNS vasospasm, led to clinical improvement in our patients over the course of 5-9 years. All of them had MRIs done at the initiation of therapy and 5-9 years after being on therapy. MRI measures of T2 lesion volumes (LVs) and number were obtained. All three patients had a good response in controlling clinical symptoms related to CNS vasospasm, Raynaud's phenomenon, visual disturbances, confusion, headaches, and hearing loss. There was also a resolution in the MRI findings of these patients. This case series of three patients shows a clinical improvement and decrease in T2 LV and number in patients with APLA and Raynaud's syndrome on centrally acting calcium channel blockers. RCVS is much more common than that currently appreciated. APLA is the common cause of RCVS. Further studies are needed to determine the optimal methods to diagnose RCVS and optimal therapies to treat it.